Altmann, Christoph
Burlacu, Nelu-Adrian
Preuss, Thomas
Hlousek, Annett
Eddicks, Stephan
Altmann, Christoph
Brezger, Marc
Eddicks, Stephan
Gjermeni, Erind
Hintz, Petra
Schueller, Per Otto
Schueth, Stefan
Slezakova, Tatiana
Toepel, Gerhard
Valenta, Anna
Bellmann, Barbara
Friederichs, Bernd
Fru, Chi Ira
Otto, Jürgen
Rahbarian, Shirin
Severin, Raik
Stancu, Oana
Turovets, Oleg
Golenia, Laura
,
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 29 November 2023
Accepted: 27 February 2024
First Online: 15 April 2024
Declarations
:
: The registry was in accordance with all relevant guidelines and regulations applicable in Germany. According to local regulations, neither ethics committee approval nor registration was required due to the non-interventional design and the absence of any drug effectiveness assessment.
: Written informed consent to data collection, processing, and analysis was obtained from all patients prior to data collection. Patient data were anonymized and aggregated for analysis.
: Christoph Altmann has received speaker honoraria and compensation for serving on advisory boards, as well as project, research, and event funding, and served as clinical investigator in clinical studies sponsored by Pfizer, Amgen, Amarin, Novartis, Daiichi Sankyo, and Astra Zeneca. Nelu-Adrian Burlacu, Thomas Preuss, and Annett Hlousek declare no conflict of interests. Stephan Eddicks has received speaker honoraria and event funding by Pfizer, Amgen, Amarin, Novartis, Daiichi Sankyo, and Astra Zeneca.